Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Steis, R. G., Dunbar, E. M., Chandramouli, N. B., … Sampson, J. H. (2012). REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Reardon, David A., James J. Vredenburgh, Annick Desjardins, Ronald G. Steis, Erin M. Dunbar, Nitin B. Chandramouli, Olivier Rixe, Jennifer A. Green, Thomas A. Davis, and John Howard Sampson. “REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Reardon DA, Vredenburgh JJ, Desjardins A, Steis RG, Dunbar EM, Chandramouli NB, et al. REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Reardon, David A., et al. “REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.

Reardon DA, Vredenburgh JJ, Desjardins A, Steis RG, Dunbar EM, Chandramouli NB, Rixe O, Green JA, Davis TA, Sampson JH. REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.